DexCom Future Growth

Future criteria checks 5/6

DexCom is forecast to grow earnings and revenue by 20.2% and 15% per annum respectively. EPS is expected to grow by 18.8% per annum. Return on equity is forecast to be 37.9% in 3 years.

Key information

20.2%

Earnings growth rate

18.8%

EPS growth rate

Medical Equipment earnings growth	16.2%
Revenue growth rate	15.0%
Future return on equity	37.9%
Analyst coverage	Good
Last updated	15 Apr 2024

Recent future growth updates

Recent updates

There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

May 16

Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

Mar 21

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

Mar 03

DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

Feb 13

DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly

Nov 25

Returns Are Gaining Momentum At DexCom (NASDAQ:DXCM)

Oct 21

Dexcom launches G7 glucose monitoring system in parts of Europe, Asia

Oct 04

What Is DexCom, Inc.'s (NASDAQ:DXCM) Share Price Doing?

Sep 24

DexCom: A High-Priced Medical Devices Company Remains Stuck In A Downtrend

Sep 21

DexCom promotes technology chief Leach to COO

Aug 31

DexCom (NASDAQ:DXCM) Has A Pretty Healthy Balance Sheet

Aug 01

DexCom stock down ~7% after hours as Q2 results miss expectations

Jul 28

Estimating The Intrinsic Value Of DexCom, Inc. (NASDAQ:DXCM)

Jul 13

DexCom: I Wouldn't Buy The Dip

Jul 07

Is It Time To Consider Buying DexCom, Inc. (NASDAQ:DXCM)?

Jun 24

We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

Jun 03

DexCom: Q1'22 Earnings Strong Enough To Maintain Valuation But Not To Increase It

May 01

DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly

Apr 12

Earnings and Revenue Growth Forecasts

NasdaqGS:DXCM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	6,064	1,113	1,167	1,605	17
12/31/2025	5,146	888	904	1,284	23
12/31/2024	4,326	679	695	1,094	23
12/31/2023	3,622	542	512	749	N/A
9/30/2023	3,403	377	500	747	N/A
6/30/2023	3,198	358	466	771	N/A
3/31/2023	3,023	293	416	754	N/A
12/31/2022	2,910	341	305	670	N/A
9/30/2022	2,793	244	261	643	N/A
6/30/2022	2,673	230	216	597	N/A
3/31/2022	2,572	258	95	486	N/A
12/31/2021	2,449	217	53	443	N/A
9/30/2021	2,319	577	140	509	N/A
6/30/2021	2,170	562	101	409	N/A
3/31/2021	2,027	530	236	502	N/A
12/31/2020	1,927	550	277	476	N/A
9/30/2020	1,821	231	264	447	N/A
6/30/2020	1,716	205	209	394	N/A
3/31/2020	1,601	148	131	305	N/A
12/31/2019	1,476	101	135	315	N/A
9/30/2019	1,351	-171	51	205	N/A
6/30/2019	1,222	-170	39	167	N/A
3/31/2019	1,128	-130	53	144	N/A
12/31/2018	1,032	-127	56	123	N/A
9/30/2018	915	43	64	131	N/A
6/30/2018	833	-5	53	110	N/A
3/31/2018	761	-33	25	83	N/A
12/31/2017	719	-50	26	92	N/A
9/30/2017	669	-48	N/A	64	N/A
6/30/2017	633	-65	N/A	51	N/A
3/31/2017	599	-88	N/A	57	N/A
12/31/2016	573	-66	N/A	56	N/A
9/30/2016	533	-57	N/A	54	N/A
6/30/2016	490	-80	N/A	49	N/A
3/31/2016	445	-64	N/A	45	N/A
12/31/2015	402	-58	N/A	49	N/A
9/30/2015	356	-58	N/A	46	N/A
6/30/2015	319	-20	N/A	40	N/A
3/31/2015	285	-23	N/A	29	N/A
12/31/2014	259	-22	N/A	24	N/A
9/30/2014	227	-26	N/A	20	N/A
6/30/2014	201	-27	N/A	10	N/A
3/31/2014	178	-31	N/A	5	N/A
12/31/2013	160	-30	N/A	2	N/A
9/30/2013	142	-36	N/A	-13	N/A
6/30/2013	122	-47	N/A	-20	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DXCM's forecast earnings growth (20.2% per year) is above the savings rate (2.3%).

Earnings vs Market: DXCM's earnings (20.2% per year) are forecast to grow faster than the US market (14.3% per year).

High Growth Earnings: DXCM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: DXCM's revenue (15% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: DXCM's revenue (15% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: DXCM's Return on Equity is forecast to be high in 3 years time (37.9%)

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

DexCom Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

DexCom, Inc. Increases Earnings Guidance for the Fiscal Year 2023

DexCom, Inc. Updates Earnings Guidance for the Year 2025

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023

Price target increased to US$121

Recent updates

Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

DexCom Is Pricey For A Reason - Its Growth Story Reflects That

Now 24% overvalued after recent price rise

DexCom, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Executive Chairman recently sold US$4.0m worth of stock

Executive Chairman notifies of intention to sell stock

DexCom, Inc. Announces the FDA Clears Stelo by Dexcom – the First Glucose Biosensor

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Executive VP notifies of intention to sell stock

DexCom: A Wealth Compounder In Healthcare

Full year 2023 earnings: EPS exceeds analyst expectations

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

DexCom, Inc. Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People

Executive Chairman recently sold US$4.6m worth of stock

DexCom: Stelo Stellar Outlook

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the t:Slim X2™ Insulin Pump by Tandem Diabetes Care in Countries Across Europe and in South Africa

DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

DexCom, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the Tandem t:slim X2 Insulin Pump

A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

Insufficient new directors

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $500 million worth of its shares.

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring with New Clinical Data Presented at EASD

DexCom, Inc. to Report Q3, 2023 Results on Oct 26, 2023

DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital

DexCom, Inc Announces the Availability of Its Dexcom One Real-Time CGM Sensor Via Reimbursement, in France

DexCom (NASDAQ:DXCM) Could Easily Take On More Debt

DexCom, Inc. Announces Appointment of Rimma Driscoll to Its Board of Directors

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom, Inc. Increases Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

DexCom, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Dexcom, Inc. Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System with Unmatched Accuracy Coming to Canadians

DexCom, Inc. Updates Earnings Guidance for the Year 2025

DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet

There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023

Full year 2022 earnings: EPS misses analyst expectations

Executive Chairman recently sold US$4.8m worth of stock

Dexcom, Inc.'s G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program

DexCom, Inc. to Report Q4, 2022 Results on Feb 09, 2023

Dexcom, Inc. Receives FDA Clearance of Next-Generation Dexcom G7 Continuous Glucose Monitoring System

DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly

Price target increased to US$121

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

DexCom, Inc. Provides Earnings Guidance for the Year 2022

DexCom, Inc. Announces the Launch of Dexcom U

Returns Are Gaining Momentum At DexCom (NASDAQ:DXCM)

DexCom, Inc. Announces Launch of Dexcom G7 in the United Kingdom, Ireland, Germany, Austria and Hong Kong – Initiating Global Rollout of World’s Most Powerful Continuous Glucose Monitoring System

Dexcom launches G7 glucose monitoring system in parts of Europe, Asia

DexCom, Inc. to Report Q3, 2022 Results on Oct 27, 2022

What Is DexCom, Inc.'s (NASDAQ:DXCM) Share Price Doing?

DexCom: A High-Priced Medical Devices Company Remains Stuck In A Downtrend

DexCom, Inc. Promotes Jacob S. Leach to Chief Operating Officer

DexCom promotes technology chief Leach to COO

DexCom, Inc. Announces One Real-Time Continuous Glucose Monitoring (rt-CGM) System Available on Prescription in the UK

DexCom (NASDAQ:DXCM) Has A Pretty Healthy Balance Sheet

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $700 million worth of its shares.